4.8 Article

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Related references

Note: Only part of the references are listed.
Review Oncology

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Danny N. Khalil et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2016)

Article Chemistry, Medicinal

Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical Candidate

Catherine A. Evans et al.

ACS MEDICINAL CHEMISTRY LETTERS (2016)

Article Immunology

Cancer-Associated Myeloid Regulatory Cells

Yannick De Vlaeminck et al.

FRONTIERS IN IMMUNOLOGY (2016)

Review Medicine, Research & Experimental

Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages

Stefano Ugel et al.

JOURNAL OF CLINICAL INVESTIGATION (2015)

Article Medicine, General & Internal

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Article Cell Biology

Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy

Steven L. Highfill et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

Review Immunology

Innate and adaptive immune cells in the tumor microenvironment

Thomas F. Gajewski et al.

NATURE IMMUNOLOGY (2013)

Review Multidisciplinary Sciences

Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?

Lisa M. Coussens et al.

SCIENCE (2013)

Review Immunology

Mechanisms and functional significance of tumour-induced dendritic-cell defects

D Gabrilovich

NATURE REVIEWS IMMUNOLOGY (2004)

Article Multidisciplinary Sciences

Central role for G protein-coupled phosphoinositide 3-kinase γ in inflammation

E Hirsch et al.

SCIENCE (2000)